Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

Eitemau Tebyg

• A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
  gan: Liu, Bai, et al.
  Cyhoeddwyd: (2016)
• The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
  gan: Wong, Hing C, et al.
  Cyhoeddwyd: (2013)
• Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
  gan: Xu, Wenxin, et al.
  Cyhoeddwyd: (2014)
• Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
  gan: Xu, Wenxin, et al.
  Cyhoeddwyd: (2015)
• Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
  gan: Liu, Bai, et al.
  Cyhoeddwyd: (2018)